ASX:NSB NeuroScientific Biopharmaceuticals (NSB) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free NSB Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get NeuroScientific Biopharmaceuticals alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About NeuroScientific BiopharmaceuticalsNeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report NSB Stock News HeadlinesMay 20, 2022 | finance.yahoo.comWe're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash WiselyMay 20, 2022 | finance.yahoo.comWe Think NeuroScientific Biopharmaceuticals (ASX:NSB) Needs To Drive Business Growth CarefullySee More Headlines Receive NSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroScientific Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NSB CUSIPN/A CIKN/A Webwww.neuroscientific.com Phone61 8 6382 1800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.01 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,070,000.00 Net Margins20.06% Pretax MarginN/A Return on Equity23.29% Return on Assets10.22% Debt Debt-to-Equity RatioN/A Current Ratio29.55 Quick Ratio3.31 Sales & Book Value Annual Sales$3.79 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares144,600,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.49 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Abby Macnish Niven B.Com.B.Sc., C.F.A., CFO & Company SecretaryDougal ThringChief Operating OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersStephen QuantrillBought 180,000 shares on 7/4/2023Total: $17,460.00 ($0.10/share)Paul RennieBought 240,134 shares on 6/1/2023Total: $24,013.40 ($0.10/share)Paul RennieBought 229,651 shares on 5/24/2023Total: $22,276.15 ($0.10/share)Anton UvarovBought 49,405 shares on 5/22/2023Total: $5,187.53 ($0.11/share)Paul RennieBought 320,968 shares on 5/17/2023Total: $26,640.34 ($0.08/share) This page (ASX:NSB) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroScientific Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
